Voluntary running does not reduce neuroinflammation or improve non-cognitive behavior in the 5xFAD mouse model of Alzheimer’s disease

被引:0
|
作者
Martina Svensson
Emelie Andersson
Oscar Manouchehrian
Yiyi Yang
Tomas Deierborg
机构
[1] Lund University,Experimental Neuroinflammation Laboratory, Department of Experimental Medical Sciences
[2] BMC B11,undefined
来源
Scientific Reports | / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Physical exercise has been suggested to reduce the risk of developing Alzheimer’s disease (AD) as well as ameliorate the progression of the disease. However, we recently published results from two large epidemiological studies showing no such beneficial effects on the development of AD. In addition, long-term, voluntary running in the 5xFAD mouse model of AD did not affect levels of soluble amyloid beta (Aβ), synaptic proteins or cognitive function. In this follow-up study, we investigate whether running could impact other pathological aspects of the disease, such as insoluble Aβ levels, the neuroinflammatory response and non-cognitive behavioral impairments. We investigated the effects of 24 weeks of voluntary wheel running in female 5xFAD mice (n = 30) starting at 2–3 months of age, before substantial extracellular plaque formation. Running mice developed hindlimb clasping earlier (p = 0.009) compared to sedentary controls. Further, running exacerbated the exploratory behavior in Elevated plus maze (p = 0.001) and anxiety in Open field (p = 0.024) tests. Additionally, microglia, cytokines and insoluble Aβ levels were not affected. Taken together, our findings suggest that voluntary wheel running is not a beneficial intervention to halt disease progression in 5xFAD mice.
引用
收藏
相关论文
共 50 条
  • [31] Targeting Neuroinflammation and Apoptosis: Cardamonin's Cognitive Benefits in Alzheimer's 5XFAD Mice
    Smail, Shukur Wasman
    NEUROCHEMICAL RESEARCH, 2025, 50 (01)
  • [32] Mitochondrial Alterations in Alzheimer's Disease: Insight from the 5xFAD Mouse Model
    Keskinoz, Elif Nedret
    Celik, Musa
    Toklucu, Ezgi Sila
    Birisik, Kerem
    Erisir, Alev
    Oz-Arslan, Devrim
    MOLECULAR NEUROBIOLOGY, 2024,
  • [33] THE EFFECTS OF ALCOHOL ON AMYLOID PATHOLOGY IN THE 5XFAD MOUSE MODEL OF ALZHEIMER'S DISEASE
    Le, L.
    Lowery, R.
    Majewska, A.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2021, 45 : 96A - 97A
  • [34] Molecular Effects of Pteryxin and Scopoletin in the 5xFAD Alzheimer's Disease Mouse Model
    Kiris, Irem
    Skalicka-Wozniak, Krystyna
    Basar, Merve Karayel
    Sahin, Betul
    Gurel, Busra
    Baykal, Ahmet Tarik
    CURRENT MEDICINAL CHEMISTRY, 2022, 29 (16) : 2937 - 2950
  • [35] Vulnerability of Spatial Pattern Separation in 5xFAD Alzheimer's Disease Mouse Model
    Gephine, Lucas
    Roux, Candice M.
    Freret, Thomas
    Boulouard, Michel
    Leger, Marianne
    JOURNAL OF ALZHEIMERS DISEASE, 2024, 97 (04) : 1889 - 1900
  • [36] Chemosensory deficits and increased apneas in the 5XFAD mouse model of Alzheimer's disease
    Sprenger, Ryan
    Romero, Phinea
    Ewald, Andrea
    Marino, Kaitlyn
    Gumnit, Maia
    McCann, Erin
    Ulland, Tyler
    Watters, Jyoti
    Baker, Tracy
    PHYSIOLOGY, 2023, 38
  • [37] Effects of Alzheimer's Disease on Bone Quality in the 5xFAD Transgenic Mouse Model
    Labre, Joan L.
    Barquera, Blanca
    Possidente, Bernard
    Vashishth, Deepak
    JOURNAL OF BONE AND MINERAL RESEARCH, 2020, 35 : 269 - 269
  • [38] Reboxetine treatment reduces neuroinflammation and neurodegeneration in the 5xFAD mouse model of Alzheimer's disease: role of CCL2
    Lopez Gutierrez, I.
    Munoz Madrigal, J. L.
    Gonzalez Prieto, M.
    Caso, J. R.
    Garcia Bueno, B.
    Gonzalez Bris, A.
    Ulecia Moron, C.
    Martin Hernandez, D.
    Leza, J. C.
    McDowell, K.
    GLIA, 2019, 67 : E610 - E610
  • [39] Reboxetine Treatment Reduces Neuroinflammation and Neurodegeneration in the 5xFAD Mouse Model of Alzheimer’s Disease: Role of CCL2
    Irene L. Gutiérrez
    Marta González-Prieto
    Javier R. Caso
    Borja García-Bueno
    Juan C. Leza
    José L. M. Madrigal
    Molecular Neurobiology, 2019, 56 : 8628 - 8642
  • [40] Reboxetine Treatment Reduces Neuroinflammation and Neurodegeneration in the 5xFAD Mouse Model of Alzheimer's Disease: Role of CCL2
    Gutierrez, Irene L.
    Gonzalez-Prieto, Marta
    Caso, Javier R.
    Garcia-Bueno, Borja
    Leza, Juan C.
    Madrigal, Jose L. M.
    MOLECULAR NEUROBIOLOGY, 2019, 56 (12) : 8628 - 8642